Payment overview · 2025
General Payments
$177.44
10 reported records · 7 companies
Healthcare provider profile · identity verified
Lorance H. Newburn, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · WAHOO, NE · NPI 1912086513
Verified facts
What the public records show
CMS Open Payments records show Lorance H. Newburn, M.D. received $177.44 in general payments during 2025 across 10 reported records.
Novartis Pharmaceuticals Corporation accounted for 43.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $76.60 | 43.2% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $19.10 | 10.8% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $18.88 | 10.6% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $18.39 | 10.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.00 | 9.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.94 | 8.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.53 | 7.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $177.44 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $76.60 | 4 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $19.10 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $19.10 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $19.10 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $18.88 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $18.88 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $18.39 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $15.11 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $14.94 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $13.53 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $13.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 313 | 57 |
| Levothyroxine Sodium | Levothyroxine Sodium | 220 | 36 |
| Gabapentin | Gabapentin | 168 | 32 |
| Atorvastatin Calcium | Atorvastatin Calcium | 154 | 42 |
| Omeprazole | Omeprazole | 148 | 31 |
| Furosemide | Furosemide | 143 | 25 |
| Losartan Potassium | Losartan Potassium | 138 | 28 |
| Tramadol Hcl | Tramadol Hcl | 135 | 28 |
| Eliquis | Apixaban | 124 | 18 |
| Potassium Chloride | Potassium Chloride | 124 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 122 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 112 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 107 | 24 |
| Lisinopril | Lisinopril | 106 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 96 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 94 | 17 |
| Warfarin Sodium | Warfarin Sodium | 84 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 77 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 77 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 73 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 71 | 13 |
| Alprazolam | Alprazolam | 69 | 12 |
| Meloxicam | Meloxicam | 69 | 16 |
| Trazodone Hcl | Trazodone Hcl | 69 | 16 |
| Xarelto | Rivaroxaban | 69 | 11 |
| Donepezil Hcl | Donepezil Hcl | 62 | 11 |
| Ozempic | Semaglutide | 59 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 58 | 46 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 55 | suppressed |
| Metformin Hcl | Metformin Hcl | 55 | 14 |
| Baclofen | Baclofen | 54 | suppressed |
| Spironolactone | Spironolactone | 54 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | suppressed |
| Famotidine | Famotidine | 52 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 52 | suppressed |
| Levetiracetam | Levetiracetam | 51 | suppressed |
| Simvastatin | Simvastatin | 48 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | suppressed |
| Carvedilol | Carvedilol | 45 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 44 | suppressed |
| Lorazepam | Lorazepam | 43 | suppressed |
| Pregabalin | Pregabalin | 40 | suppressed |
| Clonazepam | Clonazepam | 37 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 37 | 31 |
| Glimepiride | Glimepiride | 37 | suppressed |
| Prednisone | Prednisone | 36 | 35 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 33 | 33 |
| Jardiance | Empagliflozin | 31 | suppressed |
| Bupropion Xl | Bupropion Hcl | 30 | suppressed |
| Torsemide | Torsemide | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 25 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Latanoprost | Latanoprost | 24 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 22 | 14 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 19 |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Loperamide | Loperamide Hcl | 18 | suppressed |
| Nyamyc | Nystatin | 18 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Gemtesa | Vibegron | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Allopurinol | Allopurinol | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 16 | suppressed |
| Trimethoprim | Trimethoprim | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 12 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 12 |
| Ramipril | Ramipril | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | 11 |
| Atenolol | Atenolol | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $177.44 · 10 records | Novartis Pharmaceuticals Corporation | CAPVAXIVE, Cologuard Collection Kit, ENTRESTO, GARDASIL 9, LEQVIO, OPSUMIT, QULIPTA, REXULTI, UBRELVY, UPTRAVI, VAXNEUVANCE, YUPELRI | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error